Pharmanutra SpA (PHN.MI) Stock Price
Pharmanutra SpA Price
Revenue has compounded at 17.5% per year over the past 10 years to 131.69 M EUR. Earnings per share have grown at 22.8% per year over the last 10 years. Pharmanutra SpA's net margin stands at 15.2%, down from 20.2% several years earlier. Pharmanutra SpA currently offers a dividend yield of about 1.15%. The payout ratio is around 48% of earnings. The dividend has grown at 17.2% per year over the past 7 years. Analysts set a median price target of 86.70 EUR, implying 0.7% below the current price. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Pharmanutra SpA stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Pharmanutra SpA business model & stock analysis
Frequently asked questions about Pharmanutra SpA
The business model of Pharmanutra SpA revolves around producing and commercializing nutritional and dietary products. Pharmanutra SpA is a company that specializes in developing and marketing scientifically advanced food supplements, medical foods, and nutraceuticals. With a strong focus on research and innovation, Pharmanutra aims to provide high-quality products that contribute to the well-being and improve the health of individuals. Through strategic partnerships with healthcare professionals and a commitment to scientific excellence, Pharmanutra SpA strives to make a positive impact in the field of nutrition and healthcare.
Pharmanutra SpA is primarily active in the nutraceutical industry.
The main competitors of Pharmanutra SpA in the market include companies like Biogaia AB, Blackmores Limited, and Nestle S.A. They compete in the nutrition and healthcare industry, offering products that cater to various health needs. Despite facing stiff competition, Pharmanutra SpA has established a strong presence and reputation in the market, thanks to its high-quality and innovative offerings.
Pharmanutra SpA is a leading pharmaceutical company with a rich history and remarkable background. Founded in [year], the company has grown into a global provider of innovative health solutions. Pharmanutra SpA specializes in the development, manufacturing, and distribution of high-quality pharmaceutical products, catering to various medical needs. With a strong commitment to research and development, Pharmanutra SpA has emerged as a trusted name in the industry, consistently delivering effective and safe treatments. The company's dedication to cutting-edge technology, uncompromising quality standards, and customer-centric approach has established it as a frontrunner in the pharmaceutical sector, making Pharmanutra SpA a reliable choice for those seeking advanced healthcare solutions.
Pharmanutra SpA, a leading pharmaceutical company, has reached significant milestones in its journey. The company has successfully developed groundbreaking products and therapies, enhancing the healthcare industry. Pharmanutra SpA has exhibited remarkable growth and innovation, excelling in research and development to deliver high-quality healthcare solutions. Through strategic collaborations and partnerships, the company has expanded its global reach and gained recognition for its exceptional contributions to medical advancements. Pharmanutra SpA's commitment to excellence and its dedication to improving patient care have resulted in numerous accolades and industry awards. These milestones highlight the company's relentless pursuit of innovation and its unwavering commitment to improving the well-being of individuals worldwide.
Pharmanutra SpA is primarily present in various countries and regions, including Italy, its home country, as well as other European countries such as France, Germany, Spain, and the United Kingdom. Additionally, Pharmanutra SpA has expanded its presence internationally, reaching markets in North America, specifically the United States and Canada. With a global presence, Pharmanutra SpA continues to serve consumers and healthcare professionals with their innovative and high-quality nutraceutical products.
Pharmanutra SpA is a leading company in the pharmaceutical industry, representing strong values and a distinctive corporate philosophy. With a focus on innovation and scientific research, Pharmanutra is dedicated to improving the health and well-being of individuals. The company places great emphasis on quality and safety standards, ensuring that their products meet the highest industry regulations. Pharmanutra SpA also values sustainability and social responsibility, actively contributing to the communities they operate in. By combining excellence, integrity, and a customer-centric approach, Pharmanutra SpA remains committed to delivering innovative healthcare solutions that positively impact people's lives.
Analysts currently set an average price target of 83.98 EUR for the Pharmanutra SpA stock (median: 86.70 EUR), implying -2.1 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Pharmanutra SpA stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Pharmanutra SpA to generate revenue of 159.83 M EUR and earnings per share of 2.61 EUR.
The Pharmanutra SpA share (PHN.MI) is listed on 6 stock exchanges, including: Frankfurt (761.F), München (761.MU), Düsseldorf (761.DU), Mailand (PHN.MI).
Pharmanutra SpA is a leading provider of innovative and high-quality dietary supplements, medical foods, and nutraceuticals. The company was founded in Italy in 1993 and is headquartered in Pisa. The company operates internationally with offices in France, Germany, England, Spain, and the USA. Pharmanutra is divided into several business divisions that have their own research and development departments, production facilities, and distribution channels. The main area is the development and production of functional foods and medical foods that meet the medical needs of various diseases and disorders. This includes products to support gastrointestinal tract, kidney, and liver function, as well as products for clinical nutrition. Another important business area is the production of dietary supplements that support optimal nutrient and vitamin intake. The focus here is on high-quality products that have high bioavailability and excellent tolerability. Pharmanutra mainly distributes its products through pharmacies, but also through online shops and direct sales channels. The customers include end consumers as well as doctors, hospitals, and clinics. The company operates a comprehensive quality management system in accordance with national and international standards such as GMP (Good Manufacturing Practice) and ISO 9001:2015. This ensures the monitoring and assurance of product quality and safety. A special focus of the company is on research and development of new products. The company collaborates closely with universities, specialists, and research institutes to develop innovative product ideas and test their effectiveness and safety. In summary, Pharmanutra is a leading provider of functional foods, medical foods, and dietary supplements. The company is divided into several business divisions that have their own research and development departments, production facilities, and distribution channels. With its high-quality and innovative products, the company focuses on improving people's health and well-being.
The expected revenue of Pharmanutra SpA is 159.83 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Pharmanutra SpA is 24.84 M EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Pharmanutra SpA is currently 33.47. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Pharmanutra SpA stock.
The price-to-sales ratio (P/S) of Pharmanutra SpA is currently 5.20. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Pharmanutra SpA stock.
The Eulerpool Quality Score for Pharmanutra SpA is 10/10.
The ISIN of Pharmanutra SpA is IT0005274094. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Pharmanutra SpA is A2DU6N. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Pharmanutra SpA is PHN.MI. The ticker symbol is used to trade Pharmanutra SpA shares on the stock exchange.
Pharmanutra SpA stock
All fundamentals and in-depth analysis of Pharmanutra SpA
Our stock analysis for Pharmanutra SpA stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Pharmanutra SpA. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.